JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

TG Therapeutics Inc

Закрыт

СекторЗдравоохранение

33.35 -0.24

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

33.18

Макс.

33.62

Ключевые показатели

By Trading Economics

Доход

23M

28M

Продажи

20M

141M

P/E

Средняя по отрасли

90.051

37.461

Рентабельность продаж

19.97

Сотрудники

370

EBITDA

25M

38M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+31.97% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

3 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

1B

5.6B

Предыдущая цена открытия

33.59

Предыдущая цена закрытия

33.35

Новостные настроения

By Acuity

50%

50%

145 / 371 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

TG Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 окт. 2025 г., 18:41 UTC

Отчет

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 окт. 2025 г., 18:31 UTC

Отчет

Correction to Procter & Gamble to Focus on Innovation

24 окт. 2025 г., 16:25 UTC

Главные движущие силы рынка

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 окт. 2025 г., 21:24 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

24 окт. 2025 г., 21:24 UTC

Обсуждения рынка

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 окт. 2025 г., 21:07 UTC

Отчет

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 окт. 2025 г., 20:58 UTC

Отчет

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 окт. 2025 г., 20:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

24 окт. 2025 г., 20:40 UTC

Отчет

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 окт. 2025 г., 20:24 UTC

Отчет

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 окт. 2025 г., 20:23 UTC

Отчет

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 окт. 2025 г., 20:13 UTC

Отчет

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 окт. 2025 г., 20:07 UTC

Обсуждения рынка

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 окт. 2025 г., 19:40 UTC

Обсуждения рынка

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 окт. 2025 г., 19:35 UTC

Обсуждения рынка

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 окт. 2025 г., 19:33 UTC

Отчет

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 окт. 2025 г., 19:29 UTC

Обсуждения рынка

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 окт. 2025 г., 18:52 UTC

Отчет

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 окт. 2025 г., 18:41 UTC

Отчет

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 окт. 2025 г., 18:03 UTC

Отчет

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 окт. 2025 г., 18:02 UTC

Отчет

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 окт. 2025 г., 18:00 UTC

Обсуждения рынка

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 окт. 2025 г., 16:57 UTC

Отчет

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 окт. 2025 г., 16:54 UTC

Обсуждения рынка

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 окт. 2025 г., 16:44 UTC

Обсуждения рынка
Отчет

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 окт. 2025 г., 16:39 UTC

Обсуждения рынка
Отчет

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 окт. 2025 г., 16:33 UTC

Отчет

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 окт. 2025 г., 16:23 UTC

Отчет

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 окт. 2025 г., 16:20 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

24 окт. 2025 г., 16:07 UTC

Отчет

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Сравнение c конкурентами

Изменение цены

TG Therapeutics Inc Прогноз

Целевая цена

By TipRanks

31.97% рост

Прогноз на 12 месяцев

Средняя 44 USD  31.97%

Максимум 60 USD

Минимум 11 USD

Основано на мнении 4 аналитиков Wall Street, спрогнозировавших целевые цены для TG Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

4 ratings

3

Покупка

0

Удержание

1

Продажа

Техническая оценка

By Trading Central

N/A / 34.86Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bullish Evidence

Настроения

By Acuity

145 / 371Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat